The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

Cancer Cell

Volumn 8, Issue 4, 2005, Pages 287-297

  She, Qing Bai ^a   Solit, David B ^a   Ye, Qing ^a   O'Reilly, Kathryn E ^a   Lobo, Jose ^a   Rosen, Neal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN KINASE B; SERINE;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITION; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SENSITIZATION; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 26644449670     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.09.006     Document Type: Article

References (53)

1. D.R. Alessi, and P. Cohen Mechanism of activation and function of protein kinase B Curr. Opin. Genet. Dev. 8 1998 55 62
2. J. Baselga, D. Pfister, M.R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D'Andrea, A. Seidman, L. Norton, and K. Gunnett Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J. Clin. Oncol. 18 2000 904 914
3. J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D.G. Kieback, S.B. Kaye, L. Gianni, A. Harris, and T. Bjork Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J. Clin. Oncol. 20 2002 4292 4302
4. A.D. Basso, D.B. Solit, P.N. Munster, and N. Rosen Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 Oncogene 21 2002 1159 1166
5. B. Bedogni, M.S. O'Neill, S.M. Welford, D.M. Bouley, A.J. Giaccia, N.C. Denko, and M.B. Powell Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice Cancer Res. 64 2004 2552 2560
6. R. Bianco, I. Shin, C.A. Ritter, F.M. Yakes, A. Basso, N. Rosen, J. Tsurutani, P.A. Dennis, G.B. Mills, and C.L. Arteaga Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene 22 2003 2812 2822
7. A. Bonni, A. Brunet, A.E. West, S.R. Datta, M.A. Takasu, and M.E. Greenberg Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms Science 286 1999 1358 1362
8. A. Chakravarti, A. Chakladar, M.A. Delaney, D.E. Latham, and J.S. Loeffler The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner Cancer Res. 62 2002 4307 4315
9. S.R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M.E. Greenberg Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 1997 231 241
10. S.R. Datta, A. Katsov, L. Hu, A. Petros, S.W. Fesik, M.B. Yaffe, and M.E. Greenberg 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation Mol. Cell 6 2000 41 51
11. A. De Luca, A. Casamassimi, M.P. Selvam, S. Losito, F. Ciardiello, S. Agrawal, D.S. Salomon, and N. Normanno EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells Int. J. Cancer 80 1999 589 594
12. A.J. Ekstrand, N. Longo, M.L. Hamid, J.J. Olson, L. Liu, V.P. Collins, and C.D. James Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification Oncogene 9 1994 2313 2320
13. X. Fang, S. Yu, A. Eder, M. Mao, R.C. Bast Jr., D. Boyd, and G.B. Mills Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway Oncogene 18 1999 6635 6640
14. R.I. Fernando, and J. Wimalasena Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt Mol. Biol. Cell 15 2004 3266 3284
15. L. Frederick, X.Y. Wang, G. Eley, and C.D. James Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas Cancer Res. 60 2000 1383 1387
16. C. Garcia-Echeverria, M.A. Pearson, A. Marti, T. Meyer, J. Mestan, J. Zimmermann, J. Gao, J. Brueggen, H.G. Capraro, and R. Cozens In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase Cancer Cell 5 2004 231 239
17. A.P. Gilmore, A.J. Valentijn, P. Wang, A.M. Ranger, N. Bundred, M.J. O'Hare, A. Wakeling, S.J. Korsmeyer, and C.H. Streuli Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor J. Biol. Chem. 277 2002 27643 27650
18. P.M. Harari Epidermal growth factor receptor inhibition strategies in oncology Endocr. Relat. Cancer 11 2004 689 708
19. J. Hayakawa, M. Ohmichi, H. Kurachi, Y. Kanda, K. Hisamoto, Y. Nishio, K. Adachi, K. Tasaka, T. Kanzaki, and Y. Murata Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin Cancer Res. 60 2000 5988 5994
20. H.S. Huang, M. Nagane, C.K. Klingbeil, H. Lin, R. Nishikawa, X.D. Ji, C.M. Huang, G.N. Gill, H.S. Wiley, and W.K. Cavenee The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling J. Biol. Chem. 272 1997 2927 2935
21. H.Y. Lee, H. Srinivas, D. Xia, Y. Lu, R. Superty, R. LaPushin, C. Gomez-Manzano, A.M. Gal, G.L. Walsh, and T. Force Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent pathways cooperate to maintain lung cancer cell survival J. Biol. Chem. 278 2003 23630 23638
22. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, S.I. Wang, J. Puc, C. Miliaresis, L. Rodgers, and R. McCombie PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947
23. S.D. Markowitz, K. Molkentin, C. Gerbic, J. Jackson, T. Stellato, and J.K. Willson Growth stimulation by coexpression of transforming growth factor-α and epidermal growth factor-receptor in normal and adenomatous human colon epithelium J. Clin. Invest. 86 1990 356 362
24. S.D. Markowitz, L. Myeroff, M.J. Cooper, J. Traicoff, M. Kochera, J. Lutterbaugh, M. Swiriduk, and J.K. Willson A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-β independence without inactivating the p53 tumor suppressor gene J. Clin. Invest. 93 1994 1005 1013
25. J. Mendelsohn, and J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565
26. M.M. Moasser, A. Basso, S.D. Averbuch, and N. Rosen The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells Cancer Res. 61 2001 7184 7188
27. D.K. Moscatello, M. Holgado-Madruga, D.R. Emlet, R.B. Montgomery, and A.J. Wong Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor J. Biol. Chem. 273 1998 200 206
28. D.W. Nicholson, A. Ali, N.A. Thornberry, J.P. Vaillancourt, C.K. Ding, M. Gallant, Y. Gareau, P.R. Griffin, M. Labelle, and Y.A. Lazebnik Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis Nature 376 1995 37 43
29. M. Nusse, W. Beisker, C. Hoffmann, and A. Tarnok Flow cytometric analysis of G1- and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements Cytometry 11 1990 813 821
30. M.A. Olayioye, R.M. Neve, H.A. Lane, and N.E. Hynes The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J. 19 2000 3159 3167
31. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, and T.J. Boggon EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
32. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, and L. Fulton EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. USA 101 2004 13306 13311
33. W. Pao, T.Y. Wang, G.J. Riely, V.A. Miller, Q. Pan, M. Ladanyi, M.F. Zakowski, R.T. Heelan, M.G. Kris, and H.E. Varmus KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med. 2 2005 e17 10.1371/journal.pmed.0020017
34. T.G. Ram, H.L. Hosick, and S.P. Ethier Heregulin-β is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells J. Cell. Physiol. 183 2000 301 313
35. S. Ramaswamy, N. Nakamura, F. Vazquez, D.B. Batt, S. Perera, T.M. Roberts, and W.R. Sellers Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway Proc. Natl. Acad. Sci. USA 96 1999 2110 2115
36. M. Rojas, S. Yao, and Y.Z. Lin Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor J. Biol. Chem. 271 1996 27456 27461
37. D.S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno Epidermal growth factor-related peptides and their receptors in human malignancies Crit. Rev. Oncol. Hematol. 19 1995 183 232
38. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S.M. Powell, and G.J. Riggins High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
39. M.P. Scheid, K.M. Schubert, and V. Duronio Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase J. Biol. Chem. 274 1999 31108 31113
40. J.S. Sebolt-Leopold MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors Curr. Pharm. Des. 10 2004 1907 1914
41. Q.B. She, W.Y. Ma, M. Wang, A. Kaji, C.T. Ho, and Z. Dong Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved Oncogene 22 2003 2143 2150
42. Q.B. She, D. Solit, A. Basso, and M.M. Moasser Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling Clin. Cancer Res. 9 2003 4340 4346
43. D.M. Shin, N.J. Donato, R. Perez-Soler, H.J. Shin, J.Y. Wu, P. Zhang, K. Lawhorn, F.R. Khuri, B.S. Glisson, and J. Myers Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer Clin. Cancer Res. 7 2001 1204 1213
44. S.P. Soltoff, K.L. Carraway III, S.A. Prigent, W.G. Gullick, and L.C. Cantley ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor Mol. Cell. Biol. 14 1994 3550 3558
45. M. Srethapakdi, F. Liu, R. Tavorath, and N. Rosen Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest Cancer Res. 60 2000 3940 3946
46. C. Thomas, G. Ely, C.D. James, R. Jenkins, M. Kastan, A. Jedlicka, P. Burger, and R. Wharen Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells Acta Neuropathol. (Berl.) 101 2001 605 615
47. H. Tsao, V. Goel, H. Wu, G. Yang, and F.G. Haluska Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma J. Invest. Dermatol. 122 2004 337 341
48. A.R. Uzgare, and J.T. Isaacs Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells Cancer Res. 64 2004 6190 6199
49. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, C.M. Jones, C.J. Marshall, C.J. Springer, D. Barford, and R. Marais Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
50. J.R. Woodburn The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol. Ther. 82 1999 241 250
51. E. Yang, J. Zha, J. Jockel, L.H. Boise, C.B. Thompson, and S.J. Korsmeyer Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death Cell 80 1995 285 291
52. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2 2001 127 137
53. J. Zha, H. Harada, E. Yang, J. Jockel, and S.J. Korsmeyer Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell 87 1996 619 628